Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afuresertib - Laekna Therapeutics

Next Previous
X
Search
Drug Profile

Afuresertib - Laekna Therapeutics

Alternative Names: 2110183; Afuresertib hydrochloride; ASB-183; GSK-2110183; GSK2110183B; GSK2110183C; LAE 002

Latest Information Update: 28 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; Laekna Therapeutics; Novartis Oncology; University Health Network
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Phase II Ovarian cancer
  • Phase I/II Prostate cancer; Solid tumours
  • Discontinued Cancer; Chronic lymphocytic leukaemia; Gastric cancer; Haematological malignancies; Histiocytosis; Multiple myeloma

Most Recent Events

  • 28 Jun 2024 Laekna Limited completes a phase II PROFECTA-II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in China, USA (PO, Tablet) (NCT04374630)
  • 17 Jun 2024 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) prior to June 2024 (NCT04851613)
  • 17 Jun 2024 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) prior to June 2024 (NCT04851613)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top